WHO Has Released Guidelines Concerning the Health of Trans and Gender-Diverse People

A guideline on the health of trans and gender-diverse people is being developed by WHO’s Departments of Gender, Rights, and Equity – Diversity, Equity and Inclusion (GRE-DEI), Global HIV, programs of Hepatitis and Sexually Transmitted Infections (HHS), and Sexual and Reproductive Health and Research (SRH), etc. Evidence and implementation guidance on health sector initiatives focused on increasing the assessment and utilization of quality and respectful health services by trans and gender-diverse people will be provided by this new guideline.

Also Read: Orophile: A Person Who Love Mountains

Focused areas

The guidelines will concentrate on five areas:

• Gender-affirming care also includes hormones.
• Education and training for health staff to provide gender-inclusive care.
• Providing health treatment based on the needs of transgender and gender non-conforming individuals who experienced interpersonal violence.
• Health policies that encourage care that is gender inclusive.
• Legal validation of one’s own gender identity.

Also Read: 15 Women psychologists Who made their contribution to the field

Participating members

People from all WHO regions will form a Guideline Development Group (GDG) in their individual capacities, without representing any affiliated organization, while adhering to WHO guidance for creating guidelines. The organization does not commission GDG members and does not provide them with monetary compensation. The WHO technical team selected the GDG members for this guideline from among researchers with pertinent technical experience, and users (healthcare professionals and program managers), and representatives of transgender and gender variant community organizations.

Role of GDG

The GDG will convene at WHO headquarters in Geneva between February 19 and 21, 2024, to:

• The concept of grading the recommendations, assessment, development, and evaluation (GRADE) should analyze the evidence profiles or other assessments of the quality of evidence used to inform the recommendations in the five previously indicated areas.
• Evaluate the data while explicitly taking the overall balance of benefits and risks into account.
• Make recommendations while considering the advantages, disadvantages, values, and preferences as well as practicality, equity, acceptability, resource requirements, and other relevant issues.
• Cite research gaps and make implementation considerations for the guidelines.

The public and interested organizations are able to see the biographies of the GDG members of this guideline and share their opinions with WHO in accordance with the WHO policy on conflict of interest. There are 21 people on the list.